Qiagen (QGEN) Q4 2024 earnings summary

Executive summary

• Q4 and FY 2024 net sales and adjusted EPS exceeded outlook, with Q4 net sales at $521M (+3% CER) and adjusted EPS at $0.61 CER; FY net sales surpassed $1.985B CER and adjusted EPS reached $2.20 CER, both above guidance.

• Over 85% of sales are highly recurring, supporting resilience and growth in a volatile environment.

• Key growth pillars (QIAstat-Dx, QuantiFERON, QIAcuity, Sample Technologies, QDI) delivered $1.39B in 2024 sales, 99.3% of target.

• Free cash flow rose 63% to $506M in FY 2024, reflecting efficiency gains and portfolio optimization.

• Strategic milestones included FDA clearances, new system launches, expanded AI-driven bioinformatics, and organizational redesign.

Financial highlights

• Q4 2024 net sales: $521M (+3% CER); core business up 4% CER.

• Adjusted diluted EPS: $0.61 CER in Q4, $2.20 CER for 2024.

• Adjusted operating income margin: 30.6% in Q4 (+2.6pp YoY), 28.7% for 2024 (+1.8pp YoY).

• Free cash flow: $506M in 2024, up 63% YoY; operating cash flow: $674M, up 47% YoY.

• Group liquidity at year-end was $1.15B; leverage ratio improved to 0.3x.

Outlook and guidance

• 2025 net sales expected to grow ~4% CER; core business +5% CER; adjusted diluted EPS outlook for 2025: at least $2.28 CER.

• Q1 2025 net sales growth outlook: ~3% CER; adjusted EPS at least $0.50 CER.

• Adjusted operating income margin targeted to increase ≥150 bps to >30% in FY 2025.

• Currency expected to have a ~-2pp adverse impact on sales and ~$0.02–$0.03 on EPS for FY 2025.

• 2028 targets: 7% sales CAGR (core), 31% adjusted operating margin, $2B from growth pillars, $1B+ shareholder returns.